IONIS PHARMACEUTICALS INC (IONS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4622221004
IONIS PHARMACEUTICALS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 943.71 m USD |
| Gross profit | 927.80 m USD |
| Operating income | -381.68 m USD |
| EBIT | -362.34 m USD |
| Net income | -381.39 m USD |
| Diluted EPS – continuing operations | -2.38 USD |
Full history since 1990, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
More stocks
- Yunnan Yuntianhua Co Ltd (600096.SS)
- Sanan Optoelectronics Co Ltd (600703.SS)
- Infrastrutture Wireless Italiane SpA (INW.MI)
- WT Microelectronics Co Ltd (3036.TW)
- MonotaRO Co Ltd (3064.T)
- AGC Inc (5201.T)
- De' Longhi SpA (DLG.MI)
- Shandong Nanshan Aluminium Co Ltd (600219.SS)
- KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (KTOS)
- AXIS CAPITAL HOLDINGS LTD (AXS)
- Compagnie De l'odet SE (ODET.PA)
- Swancor Advanced Materials Co Ltd (688585.SS)
Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.